<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05110742</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0526</org_study_id>
    <nct_id>NCT05110742</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances</brief_title>
  <official_title>Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety, efficacy and optimal cell dose of CAR 5/IL15-transduced CB-NK cells&#xD;
      in patients with relapsed/refractory T-cell malignances, mantle cell lymphoma, and chronic&#xD;
      lymphocytic leukemia. The efficacy and optimal dose will be identified for individual&#xD;
      diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective:&#xD;
&#xD;
      To determine the safety, efficacy and optimal cell dose of CAR.5/IL15-transduced CB-NK cells&#xD;
      in patients with relapsed/refractory T-cell malignances, mantle cell lymphoma, and chronic&#xD;
      lymphocytic leukemia. The efficacy and optimal dose will be identified for individual&#xD;
      diseases.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To assess the overall response rate (complete and partial response rates)&#xD;
&#xD;
        -  To quantify persistence of infused allogeneic donor CAR-transduced CB-derived NK cells&#xD;
           in -To conduct comprehensive immune reconstitution studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 31, 2022</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>General grading:&#xD;
Grade 1: Mild: discomfort present with no disruption of daily activity, no treatment required beyond prophylaxis.&#xD;
Grade 2: Moderate: discomfort present with some disruption of daily activity, require treatment.&#xD;
Grade 3: Severe: discomfort that interrupts normal daily activity, not responding to first line treatment.&#xD;
Grade 4: Life Threatening: discomfort that represents immediate risk of death</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Hematological Malignancy</condition>
  <arm_group>
    <arm_group_label>Phase 1 Dose Level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAR.5/IL15-transduced CB-NK cells Dose level 1, 1e7 cryopreserved cells flat dose Dose level 2, 1e8 cryopreserved cells flat dose Dose level 3, 1e9 cryopreserved cells flat dose Dose level 4, 1e10 cryopreserved cells flat dose&#xD;
All patients will receive Lymphodepleting Chemotherapy of Cyclophosphamide and Fludarabine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Dose Level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized between the 2 optimal doses of CAR.5/IL15-transduced CB-NK cells determined by Phase 1.&#xD;
All patients will receive Lymphodepleting Chemotherapy of Cyclophosphamide and Fludarabine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given by IV</description>
    <arm_group_label>Phase 1 Dose Level</arm_group_label>
    <arm_group_label>Phase 2 Dose Level</arm_group_label>
    <other_name>Fludarabine</other_name>
    <other_name>Fludara®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given by IV</description>
    <arm_group_label>Phase 1 Dose Level</arm_group_label>
    <arm_group_label>Phase 2 Dose Level</arm_group_label>
    <other_name>Cytoxan®</other_name>
    <other_name>Neosar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAR.5/IL15-transduced CB-NK cells</intervention_name>
    <description>Given by IV</description>
    <arm_group_label>Phase 1 Dose Level</arm_group_label>
    <arm_group_label>Phase 2 Dose Level</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Patients with hematological malignances with an expression of CD5 in the&#xD;
             pre-enrollment tumor sample ≥ 30% measured by immunohistochemistry or flow cytometry.&#xD;
&#xD;
          2. Patients must meet diseases specific eligibility criteria (see below)&#xD;
&#xD;
          3. Patients should be at least 3 weeks from last cytotoxic chemotherapy at the time of&#xD;
             starting lymphodepleting chemotherapy. Patients may continue tyrosine kinase&#xD;
             inhibitors or other targeted therapies until at least three days prior to&#xD;
             administration of lymphodepleting chemotherapy.&#xD;
&#xD;
          4. Localized radiotherapy to one or more disease sites are allowed prior the infusion&#xD;
             provided that there are additional disease sites that are not irradiated&#xD;
&#xD;
          5. Karnofsky Performance Scale &gt; 50%.&#xD;
&#xD;
          6. Adequate organ function:&#xD;
&#xD;
               1. Renal: Serum creatinine ≤ 1.5 mg/dL or estimated Glomerular Filtration Rate (eGFR&#xD;
                  using the CKI-EPI equation) ≥ 60 ml/min/1.73 m2.&#xD;
&#xD;
               2. Hepatic: ALT/AST ≤ 2.5 x ULN or ≤ 5 x ULN if documented liver involvement with&#xD;
                  disease, Total bilirubin ≤ 1.5 mg/dL, except in subjects with Gilbert's Syndrome&#xD;
                  in whom total bilirubin must be ≤ 3.0 mg/dL. No history of liver cirrhosis. No&#xD;
                  ascites.&#xD;
&#xD;
               3. Cardiac: Cardiac ejection fraction ≥ 50%, no clinically significant pericardial&#xD;
                  effusion as determined by an ECHO or MUGA, and no uncontrolled arrhythmias or&#xD;
                  symptomatic cardiac disease.&#xD;
&#xD;
               4. Pulmonary: No clinically significant lung involvement, per PI discretion, pleural&#xD;
                  effusion, baseline oxygen saturation &gt; 92% on room air.&#xD;
&#xD;
          7. Able to provide written informed consent.&#xD;
&#xD;
          8. 18-80 years of age.&#xD;
&#xD;
          9. Weight ≥40 kg&#xD;
&#xD;
         10. All participants who are able to have children must practice effective birth control&#xD;
             while on study and up to 3 months post completion of study therapy. Acceptable forms&#xD;
             of birth control for female patients include: hormonal birth control, intrauterine&#xD;
             device, diaphragm with spermicide, condom with spermicide, or abstinence, for the&#xD;
             length of the study. If the participant is a female and becomes pregnant or suspects&#xD;
             pregnancy, she must immediately notify her doctor. If the participant becomes pregnant&#xD;
             during this study, she will be taken off this study. Men who are able to have children&#xD;
             must use effective birth control while on the study. If the male participant fathers a&#xD;
             child or suspects that he has fathered a child while on the study, he must immediately&#xD;
             notify his doctor.&#xD;
&#xD;
         11. Signed consent to long-term follow-up protocol PA17-0483.&#xD;
&#xD;
         12. Disease specific inclusion criteria A. T-cell non-Hodgkin's lymphoma and T-cell acute&#xD;
             lymphoblastic leukemia&#xD;
&#xD;
        1. Patients with history of T-lymphoid malignancies, defined as acute lymphoblastic&#xD;
        leukemia (ALL/T-LBL), Peripheral T-cell lymphoma (PTCL-NOS, MF/SS, Hepatosplenic&#xD;
        gamma/delta NHL, AITL, ALCL) who have received at least 2 lines of standard&#xD;
        chemo-immunotherapy or targeted therapy and have measurable persistent disease. For T-ALL&#xD;
        active disease defined as (&gt;5% of blasts or positive MRD at a level of &gt;0.1% measured by&#xD;
        multiparameter flow cytometry).&#xD;
&#xD;
        2. Patients with history of T-lymphoid malignancies as defined above with relapsed disease&#xD;
        following standard therapy or a stem cell transplant.&#xD;
&#xD;
        B. Chronic lymphocytic leukemia (CLL) Chronic lymphocytic leukemia (CLL) small lymphocytic&#xD;
        lymphoma (SLL), Richter's transformation of CLL or SLL who have received at least 2 lines&#xD;
        of standard chemoimmunotherapy or targeted therapy and have persistent disease C. Mantle&#xD;
        cell lymphoma Relapsed or refractory mantle cell lymphoma after 2 lines of standard&#xD;
        chemoimmunotherapy including a BTKi&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Positive beta HCG in female of child-bearing potential defined as not postmenopausal&#xD;
             for 24 months or no previous surgical sterilization or lactating females.&#xD;
&#xD;
          2. Presence of clinically significant Grade 3 or greater toxicity from the previous&#xD;
             treatment, as determined by PI.&#xD;
&#xD;
          3. Presence of uncontrolled fungal, bacterial, viral, or other infection not responding&#xD;
             to appropriate therapy.&#xD;
&#xD;
          4. Active hepatitis B or C.&#xD;
&#xD;
          5. HIV with detectable viral load&#xD;
&#xD;
          6. Presence of active neurological disorder(s).&#xD;
&#xD;
          7. Active autoimmune disease within 12 months of enrollment&#xD;
&#xD;
          8. Active cerebral or meningeal involvement by the malignancy&#xD;
&#xD;
          9. Active (defined as requiring therapy) acute or chronic GVHD&#xD;
&#xD;
         10. Any other malignancy known to be active, except for treated cervical intra-epithelial&#xD;
             neoplasia and non-melanoma skin cancer.&#xD;
&#xD;
         11. Presence of any other serious medical condition that may endanger the patient at&#xD;
             investigator criteria&#xD;
&#xD;
         12. Major surgery &lt;4 weeks prior to first dose of study drug&#xD;
&#xD;
         13. Allogeneic SCT or DLI &lt;12 weeks prior to first dose of study drug&#xD;
&#xD;
         14. Concomitant use of other investigational agents.&#xD;
&#xD;
         15. Concomitant use of other anti-cancer agents.&#xD;
&#xD;
         16. Patients receiving systemic steroid therapy at time of enrollment (physiological&#xD;
             substitutive doses are allowed), or have received ATG within 14 days or Campath within&#xD;
             28 days of enrollment.&#xD;
&#xD;
         17. Patients receiving immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>chitra hosing</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chitra Hosing</last_name>
    <phone>(713) 745-3219</phone>
    <email>cmhosing@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Chitra Hosing</last_name>
      <phone>713-745-3219</phone>
      <email>cmhosing@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

